title: [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
abstract: Patients with benign prostatic hyperplasia (BPH) received proscar (finasteride) in daily dose 5 mg for: at least 6 months (n = 206, 20.4%), 12 months (n = 513, 50.9%), 24 months (n = 164, 16.3%), 3-4 years (n = 125, 12.4%). Because the size of the prostatic gland reduced significantly (by 22%) only after one year of proscar treatment, the duration of this treatment should be continued for at least 12 months, in some patients as long as the whole life. The duration of the treatment should be decided for each individual patient. The improvement after the proscar treatment was observed in 95% of the patients treated for benign prostatic hyperplasia.
authors.forename: V N
authors.initials: VN
authors.lastname: Tkachuk
authors.forename: S Kh
authors.initials: SKh
authors.lastname: Al'-Shukri
authors.forename: V I
authors.initials: VI
authors.lastname: Kornienko
authors.forename: I V
authors.initials: IV
authors.lastname: Kuz'min
mesh_terms: D000368:Aged; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen